The potential for delivery of particulate matter through positive airway pressure devices (CPAP/BPAP).
BACKGROUND
Airborne particulate matter may induce health risk with inhalation. Special concerns exist for deployed military personnel with inhaled particulate matter in desert environments. Continuous positive airway pressure (CPAP) used in obstructive sleep apnea may facilitate inhalation of particulate matter. We evaluated the ability of commercial CPAP filter systems to eliminate inhalation of particulate matter.


METHODS
An ultrasonic medical nebulizer (DeVilbliss Ultraneb, DeVilbliss, Somerset, PA) atomized liquid producing "respirable" aerosol. Technetium-99m diethylene triamine pentaacetic acid dissolved in water was also aerosolized to quantify aerosol inhalation. A high efficiency particulate air (HEPA) filter placed at the patient-hose connection port in the bilevel positive airway pressure (BPAP) device captured the aerosol inbound to the patient. The HEPA filter provided a means to quantify aerosol dose delivered to a simulated patient. Commercial foam and ultrafine filters were assessed with aerosol to determine the simulated patient exposure.


RESULTS
Foam and ultrafine filters used together allowed 1.5% or less of aerosol volume to pass through the BPAP system. Foam filters alone allowed an average of 18.9% of aerosol delivered to pass through the BPAP system.


CONCLUSIONS
Foam and ultrafine filters used together in BPAP systems provide excellent aerosol filtration in this laboratory simulation of BPAP use.
Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA. kristoda@upmc.edu
David
D
Kristo
Timothy
T
Corcoran
Nina
N
O'Connell
Kristina
K
Thomas
Patrick
P
Strollo
D045422:Continuous Positive Airway Pressure / Q000295:instrumentation*; D004391:Dust; D004867:Equipment Design; D005374:Filtration / Q000295:instrumentation*; D006801:Humans; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D052638:Particulate Matter; D020181:Sleep Apnea, Obstructive / Q000628:therapy*; D016284:Technetium Tc 99m Pentetate
D004391:Dust; D052638:Particulate Matter; D016284:Technetium Tc 99m Pentetate
Environ Health Perspect. 2008 Mar;116(3):292-6
18335093
JAMA. 2006 Mar 8;295(10):1127-34
16522832
Epidemiology. 2008 Mar;19(2):209-16
18223484
Environ Health Perspect. 2008 Jul;116(7):907-14
18629313
Environ Monit Assess. 2007 Sep;132(1-3):155-63
17171248
Int J Environ Health Res. 2008 Jun;18(3):209-21
18569148
J Am Coll Cardiol. 2008 Aug 26;52(9):719-26
18718418
Environ Health Perspect. 2006 Aug;114(8):1215-20
16882528
Am J Transplant. 2006 Nov;6(11):2765-73
17049064